Ann Arbor Staging System for Lymphoma
Classifies Hodgkin and Non-Hodgkin lymphoma into stages I–IV based on anatomical disease distribution, with A/B symptom and E/S modifiers.
Score interpretation
→ Stage I lymphoma. Localised disease. Excellent prognosis. Involved-field radiotherapy ± short-course chemotherapy for Hodgkin lymphoma.
→ Stage II lymphoma. Regional disease. Good prognosis. Combined modality treatment for Hodgkin; CHOP-based for NHL.
→ Stage III lymphoma. Disease on both sides of diaphragm. Systemic chemotherapy required. Consider clinical trial.
→ Stage IV lymphoma. Advanced/disseminated disease. Aggressive systemic chemotherapy; evaluate for transplant eligibility.
Interpretation bands for the Ann Arbor Staging. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Fong Clinical Risk Score for Colorectal Cancer Recurrence · Oncology
- CRASH Score for Chemotherapy Risk Assessment in Elderly Patients · Oncology
- Rai Staging System for CLL · Oncology
- Follicular Lymphoma International Prognostic Index (FLIPI) · Oncology
- International Staging System for Multiple Myeloma (ISS) · Oncology
- CISNE Score for Febrile Neutropenia · Oncology
- Zoledronic Acid · Bisphosphonate (IV)
- Denosumab · RANK Ligand Inhibitor (Anti-resorptive)
- Zoledronic Acid · IV Bisphosphonate
- Obinutuzumab · Anti-CD20 Monoclonal Antibody — CLL / Follicular Lymphoma
- Idelalisib · PI3Kδ Inhibitor — CLL / Follicular Lymphoma
- Levonorgestrel Intrauterine System · Progestogen-Only Intrauterine Device
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.